GlassScriptPhysician profile
Mark K Koralewski
NPI 1992720841
$5,626.57
in general payments reported to CMS, 2019-2025
30 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $539 · 2021: $574 · 2022: $727 · 2023: $955 · 2024: $1,002 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,087.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,416.96 | 2019-2025 | |
| Viiv Healthcare Company | $727.11 | 2022-2025 | Apretude |
| Abbvie INC. | $620.44 | 2019-2024 | |
| Pfizer INC. | $436.34 | 2019-2025 | |
| Lilly USA, LLC | $431.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $202.01 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Idorsia Pharmaceuticals US INC | $180.50 | 2022-2024 | Quviviq |
| Inspire Medical Systems, INC. | $179.42 | 2024 | Inspire |
| Janssen Biotech, INC. | $165.20 | 2019-2021 | |
| Galderma Laboratories, L.P. | $142.10 | 2019 | |
| Exact Sciences Corporation | $126.43 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Leo Pharma INC. | $115.45 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $114.32 | 2019-2022 | |
| Daiichi Sankyo INC. | $93.67 | 2022-2023 | Injectafer |
| Amgen INC. | $89.67 | 2019-2025 | Repatha, Otezla |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $79.65 | 2022-2023 | Freestyle Libre 3 |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $74.21 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $61.64 | 2023 | Rexulti |
| Dexcom, INC. | $57.34 | 2024-2025 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $52.66 | 2019-2021 | |
| Celgene Corporation | $44.35 | 2019 | |
| Astellas Pharma US INC | $37.25 | 2023-2024 | Veozah |
| Merck Sharp & Dohme LLC | $33.05 | 2019-2023 | Dificid |
| Hologic Sales and Service, LLC | $32.62 | 2024 | Aptima |
| Dermira, INC. | $28.18 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.82 | 2021 | |
| Glaxosmithkline, LLC. | $17.02 | 2024 | Shingrix, Arexvy |
| Dynavax Technologies Corporation | $16.65 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $16.54 | 2020 | |
| Sanofi Pasteur INC. | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Koralewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.